Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.
Location: United States
Employees: 1-10
Total raised: $41.25M
Founded date: 2020
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.08.2025 | Series B | $11.25M | Eli Lilly ... |
| 04.04.2022 | Series B | $30M | - |
Mentions in press and media 3
| Date | Title | Description |
| 28.08.2025 | Incyclix Bio: $11.25 Million Series B Extension Secured For Treating Resistant Cancer | Incyclix Bio is a company working on advanced cancer treatments. They are developing a new drug called INX-315, a potent and selective inhibitor targeting CDK2, a protein that regulates the cell cycle. This drug aims to treat severe and res... |
| 04.04.2022 | Incyclix Bio Raises $30M in Series B Financing | Incyclix Bio, a Reserch Thriangle Park, NC-based cell cycle control company, raised $30M in Series B funding. The round was led by Boxer Capital with participation from RA Capital Management and Eshelman Ventures. Sid Subramony, Ph.D., Vice... |
| - | Incyclix Bio | “ARC Therapeutics Oncology Therapeutics” |